New Clinical Trial for Mesothelioma
Key Takeaways A new clinical trial tested pegargiminase combined with chemotherapy specifically for patients with non-epithelioid pleural mesothelioma — the most aggressive and hardest-to-treat subtypes (sarcomatoid and biphasic). The results were remarkable: median survival for enrolled patients went from 1.6 months to 36 months — a dramatic improvement for a subtype that historically has the […]
